Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT03586661 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Deleterious BRCA1 Gene Mutation
Deleterious BRCA2 Gene Mutation
Endometrial Adenocarcinoma
High Grade Ovarian Serous Adenocarcinoma
Platinum-Resistant Ovarian Carcinoma
Primary Peritoneal High Grade Serous Adenocarcinoma
Progressive Disease
Recurrent Endometrial Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions

DRUG: Copanlisib
DRUG: Niraparib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]